JP2018515499A5 - - Google Patents

Download PDF

Info

Publication number
JP2018515499A5
JP2018515499A5 JP2017557942A JP2017557942A JP2018515499A5 JP 2018515499 A5 JP2018515499 A5 JP 2018515499A5 JP 2017557942 A JP2017557942 A JP 2017557942A JP 2017557942 A JP2017557942 A JP 2017557942A JP 2018515499 A5 JP2018515499 A5 JP 2018515499A5
Authority
JP
Japan
Prior art keywords
tautomer
pharmaceutically acceptable
solvate
compound according
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017557942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515499A (ja
Filing date
Publication date
Priority claimed from ES201530608A external-priority patent/ES2593057B1/es
Application filed filed Critical
Publication of JP2018515499A publication Critical patent/JP2018515499A/ja
Publication of JP2018515499A5 publication Critical patent/JP2018515499A5/ja
Pending legal-status Critical Current

Links

JP2017557942A 2015-05-05 2016-04-27 Gpr55受容体の活性の選択的モジュレーター:クロメノピラゾール誘導体 Pending JP2018515499A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201530608A ES2593057B1 (es) 2015-05-05 2015-05-05 Moduladores selectivos de la actividad del receptor GPR55: derivados de cromenopirazol
ESP201530608 2015-05-05
PCT/ES2016/070314 WO2016177922A1 (es) 2015-05-05 2016-04-27 Moduladores selectivos de la actividad del receptor gpr55: derivados de cromenopirazol

Publications (2)

Publication Number Publication Date
JP2018515499A JP2018515499A (ja) 2018-06-14
JP2018515499A5 true JP2018515499A5 (https=) 2019-06-06

Family

ID=57217626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017557942A Pending JP2018515499A (ja) 2015-05-05 2016-04-27 Gpr55受容体の活性の選択的モジュレーター:クロメノピラゾール誘導体

Country Status (13)

Country Link
US (1) US10435412B2 (https=)
EP (1) EP3305794B1 (https=)
JP (1) JP2018515499A (https=)
KR (1) KR20180002717A (https=)
CN (1) CN107735397A (https=)
AU (1) AU2016257025A1 (https=)
BR (1) BR112017023834A2 (https=)
CA (1) CA2985021A1 (https=)
ES (1) ES2593057B1 (https=)
IL (1) IL255420A0 (https=)
MX (1) MX2017014145A (https=)
RU (1) RU2017138563A (https=)
WO (1) WO2016177922A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109420174B (zh) * 2017-08-31 2021-07-13 清华大学 Gpr18及其调节剂在防治免疫系统疾病中的应用
CN109420173B (zh) * 2017-08-31 2021-07-13 清华大学 Gpr55及其调节剂在防治免疫系统疾病中的应用
EP4472947A1 (en) * 2022-03-07 2024-12-11 Firmenich Incorporated Sweetener compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3624102A (en) * 1969-05-21 1971-11-30 Warner Lambert Co Substituted benzopyranopyrazoles
GB0010960D0 (en) 2000-05-05 2000-06-28 Glaxo Group Ltd Assay
WO2004074844A1 (en) * 2003-02-18 2004-09-02 Astrazeneca Ab Screening assays for cannabinoid-ligand-type modulators of gpr55
EP2079736B1 (en) * 2006-12-29 2017-10-18 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
WO2009010824A1 (en) * 2007-07-13 2009-01-22 Glenmark Pharmaceuticals, S.A. Dihydrochromenopyrazole derivatives as vanilloid receptor ligands
ES2345592B1 (es) * 2009-03-24 2011-07-21 Consejo Superior De Investigaciones Cientificas (Csic), 70% Derivados de cromenopirazoles como ligandos de receptores de cannabinoides.
WO2014013117A1 (es) * 2012-07-18 2014-01-23 Consejo Superior De Investigaciones Científicas (Csic) Cromenopirazoldionas como derivados cannabinoides de quinonas con actividad antitumoral
ES2548789B1 (es) 2014-03-18 2016-08-08 Consejo Superior De Investigaciones Científicas (Csic) Nuevas cromenoquinonas moduladoras de receptores cannabinoidescb2 con actividad antitumoral

Similar Documents

Publication Publication Date Title
RU2410378C2 (ru) Сульфоксиминзамещенные пиримидины в качестве ингибиторов cdk и/или vegf, их получение и применение в качестве лекарственных средств
JP2017502940A5 (https=)
JP2011502958A5 (https=)
RU2012136451A (ru) Композиции и способы улучшения активности протеасомы
JP2014523851A5 (https=)
JP2012519179A5 (https=)
RU2018114518A (ru) Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca)
JP2012532137A5 (https=)
JP2013512903A5 (https=)
RU2017126187A (ru) 5-[(пиперазин-1-ил)-3-оксо-пропил]-имидазолидин-2,4-дионовые производные в качестве ингибиторов adamts для лечения остеоартрита
JP2018530549A5 (https=)
RU2013108641A (ru) Способ лечения офтальмологических заболеваний с использованием соединений ингибиторов киназы в пролекарственных формах
NZ598294A (en) Heterocyclic compounds for the inhibition of pask
JP2011006480A5 (https=)
JP2005526723A5 (https=)
RU2012134306A (ru) Азотосодержащие производные гетероарилов
JP2018502906A5 (https=)
RU2013126094A (ru) Замещённые пиразолопиримидины как активаторы глюкоцереброзидазы
RU2005136368A (ru) Производные пиперазина и их применение для лечения неврологических и психиатрических заболеваний
JP2012520238A5 (https=)
WO2016089060A2 (en) Heterocyclic derivatives and use thereof
JP2019537603A5 (https=)
RU2015117647A (ru) Новые производные пиразола
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
MA34047B1 (fr) Polymorphes et solvates de chlorhydrate de 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine